BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental
laser manufacturer and distributor, today announced the introduction
of the EPIC 10?, the next generation of BIOLASE's Total Diode
Solution. The EPIC 10 is being demonstrated at CDA Presents: Anaheim
2012, the California Dental Association's annual tradeshow, being held
May 3-5 at the Anaheim Convention Center in Anaheim, CA, and several
other concurrent and upcoming dental industry events. EPIC 10 is not
yet available for sale in the U.S. as it is pending 510k clearance
from the Food and Drug Administration ("FDA").
This next generation, diode soft-tissue laser will have the shortest
pulse available in the market today. Short pulses are known to cause
less thermal damage in tissue and produce cleaner cuts. In addition,
the EPIC 10 will have a built-in battery for a full day of operation
and will be used as a design platform to build more powerful versions
with different combinations of laser wavelengths.
Federico Pignatelli, Chairman and CEO, said, "The EPIC 10 represents
yet another important innovation at BIOLASE and an evolution of diode
soft-tissue dental laser technology. The ability to combine 15 of the
most commonly performed soft-tissue procedures, including 20-minute
laser whitening and temporary oral pain relief, in one device is a
true innovation for our customers and their patients. The BIOLASE
engineering and marketing teams continue to lead the dental technology
community in advancing laser technology with a focus on providing new
tools to improve both the clinical results and the
return-on-investment of dental practices. The EPIC 10 is a great
example of such combined focus."
The EPIC 10 features a 940nm wavelength with 10 watts of real power as
well as an intuitive procedure-based graphical touchscreen. It also
uses BIOLASE's proprietary ComfortPulse? control technology that helps
to prevent potential tissue damage and keeps patients comfortable by
avoiding pain-inducing heat buildup at the surgical site.
Neither EPIC 10, nor any claims of efficacy attached to it, are yet
cleared by the FDA. There is no guarantee that the FDA will approve
the device, nor any timeframe upon which such approval may occur.
About BIOLASE Technology, Inc.BIOLASE Technology, Inc., the World's
leading Dental Laser Company, is a medical technology company that
develops, manufactures and markets dental lasers and also distributes
and markets dental imaging equipment, products that are focused on
technologies that advance the practice of dentistry and medicine. The
Company's laser products incorporate 285 patented and patent pending
technologies designed to provide clinically superior performance with
less pain and faster recovery times. Its imaging products provide
cutting-edge technology at competitive prices to deliver the best
results for dentists and patients. BIOLASE's principal products are
dental laser systems that perform a broad range of dental procedures,
including cosmetic and complex surgical applications, and a full line
of dental imaging equipment. BIOLASE has sold more than 19,000 lasers
among 16,000 customers. Other products under development address
ophthalmology and other medical and consumer markets.
For updates and information on laser and Waterlase dentistry, find
BIOLASE at http://www.biolase.com(http://www.biolase.com/), Twitter at
This press release may contain forward-looking statements within the
meaning of safe harbor provided by the Securities Reform Act of 1995
that are based on the current expectations and estimates by BIOLASE
management. These forward-looking statements can be identified through
the use of words such as "anticipates," "expects," "intends," "plans,"
"believes," "seeks," "estimates," "may," "will," and variations of
these words or similar expressions. Forward-looking statements are
based on management's current, preliminary expectations and are
subject to risks, uncertainties and other factors which may cause the
Company's actual results to differ materially from the statements
contained herein, and are described in the Company's reports it files
with the Securities and Exchange Commission, including its annual and
quarterly reports. No undue reliance should be placed on
forward-looking statements. Such information is subject to change, and
BIOLASE undertakes no obligation to update such statements.